Pharmacological and Pharmaceutical Sciences
Pharmacy Practice and Translational Research
Wang W, Albadari N, Du Y, Fowler JF, Sang HT, Xian W, McKeon F, Li W, Zhou J, Zhang R
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. Pharmacol Rev. 2024 May 02; 76(3):414-453.
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.
Zafar A, Wang W, Liu G, Wang X, Xian W, McKeon F, Foster J, Zhou J, Zhang R
Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev. 2021 03; 41(2):961-1021.
Molecular targeting therapies for neuroblastoma: Progress and challenges.
Zafar A, Wang W, Liu G, Xian W, McKeon F, Zhou J, Zhang R
Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope. Cancer Lett. 2021 01 01; 496:16-29.
Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.
Wang W, Qin JJ, Voruganti S, Nijampatnam B, Velu SE, Ruan KH, Hu M, Zhou J, Zhang R
Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Res. 2018 10 01; 78(19):5656-5667.
Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.
Wang W, Aguilar M, Datta S, Alley A, Tadesse M, Wang X, Gao X, Zhang R
Dual inhibitor of MDM2 and NFAT1 for experimental therapy of breast cancer: in vitro and in vivo anticancer activities and newly discovered effects on cancer metabolic pathways. Front Pharmacol. 2025; 16:1531667.
Dual inhibitor of MDM2 and NFAT1 for experimental therapy of breast cancer: in vitro and in vivo anticancer activities and newly discovered effects on cancer metabolic pathways.
Wang W, Du Y, Datta S, Fowler JF, Sang HT, Albadari N, Li W, Foster J, Zhang R
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable? Genes Dis. 2025 Mar; 12(2):101156.
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?
Terrell JR, Tang S, Faniyi OO, Jeong IH, Yin J, Nijampatnam B, Velu SE, Wang W, Zhang R, Luo M
Protein science : a publication of the Protein Society
Structural studies of antitumor compounds that target the RING domain of MDM2. Protein Sci. 2022 Aug; 31(8):e4367.
Structural studies of antitumor compounds that target the RING domain of MDM2.
Kaluz S, Zhang Q, Kuranaga Y, Yang H, Osuka S, Bhattacharya D, Devi NS, Mun J, Wang W, Zhang R, Goodman MM, Grossniklaus HE, Van Meir EG
Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth. Oncogene. 2021 Aug; 40(33):5182-5191.
Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth.
Ibrahim Al-Obaide MA, Arutla V, Bacolod MD, Wang W, Zhang R, Srivenugopal KS
International journal of molecular sciences
Genomic Space of MGMT in Human Glioma Revisited: Novel Motifs, Regulatory RNAs, NRF1, 2, and CTCF Involvement in Gene Expression. Int J Mol Sci. 2021 Mar 02; 22(5).
Genomic Space of MGMT in Human Glioma Revisited: Novel Motifs, Regulatory RNAs, NRF1, 2, and CTCF Involvement in Gene Expression.
Wang W, Wang X, Rajaei M, Youn JY, Zafar A, Deokar H, Buolamwini JK, Yang J, Foster JH, Zhou J, Zhang R
Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action. Cancers (Basel). 2020 Dec 05; 12(12).
Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action.
Ashraf-Uz-Zaman M, Shahi S, Akwii R, Sajib MS, Farshbaf MJ, Kallem RR, Putnam W, Wang W, Zhang R, Alvina K, Trippier PC, Mikelis CM, German NA
Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. Eur J Med Chem. 2021 Jan 01; 209:112866.
Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer.
Punganuru SR, Artula V, Zhao W, Rajaei M, Deokar H, Zhang R, Buolamwini JK, Srivenugopal KS, Wang W
Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells. 2020 Jul 01; 9(7).
Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy. Cells. 2020 05 09; 9(5).
Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy.
Wang W, Hu B, Qin JJ, Cheng J, Li X, Rajaei M, Fan J, Yang XR, Zhang R
Corrigendum to "A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance" [Genes Dis 694 (2019) 419-430]. Genes Dis. 2020 03; 7(1):160-161.
Corrigendum to "A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance" [Genes Dis 694 (2019) 419-430].
Wang W, Hu B, Qin JJ, Cheng JW, Li X, Rajaei M, Fan J, Yang XR, Zhang R
A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes Dis. 2019 Dec; 6(4):419-430.
A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance.
Wang W, Qin JJ, Rajaei M, Li X, Yu X, Hunt C, Zhang R
Targeting MDM2 for novel molecular therapy: Beyond oncology. Med Res Rev. 2020 05; 40(3):856-880.
Targeting MDM2 for novel molecular therapy: Beyond oncology.
Deokar H, Deokar M, Wang W, Zhang R, Buolamwini JK
Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents
QSAR Studies of New Pyrido[3,4-b]indole Derivatives as Inhibitors of Colon and Pancreatic Cancer Cell Proliferation. Med Chem Res. 2018 Dec; 27(11-12):2466-2481.
QSAR Studies of New Pyrido[3,4-b]indole Derivatives as Inhibitors of Colon and Pancreatic Cancer Cell Proliferation.
Wang W, Cheng JW, Qin JJ, Hu B, Li X, Nijampatnam B, Velu SE, Fan J, Yang XR, Zhang R
MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett. 2019 09 10; 459:156-167.
MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.
Qin JJ, Li X, Hunt C, Wang W, Wang H, Zhang R
Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes Dis. 2018 Sep; 5(3):204-219.
Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine.
Wang W, Qin JJ, Li X, Tao G, Wang Q, Wu X, Zhou J, Zi X, Zhang R
Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms. Carcinogenesis. 2018 07 30; 39(8):1026-1036.
Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms.
Qin JJ, Wang W, Li X, Deokar H, Buolamwini JK, Zhang R
Inhibiting ?-Catenin by ?-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Front Pharmacol. 2018; 9:5.
Inhibiting ?-Catenin by ?-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy.
Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen. Front Pharmacol. 2017; 8:917.
Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen.
Progress in molecular biology and translational science
Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway. Prog Mol Biol Transl Sci. 2017; 151:195-216.
Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway.
Future Cancer Drug Discovery Is Now. Curr Cancer Drug Targets. 2025; 25(1):1-2.
Zu Y, Zhao L, Hao L, Mechref Y, Zabet-Moghaddam M, Keyel PA, Abbasi M, Wu D, Dawson JA, Zhang R, Nie S, Moustaid-Moussa N, Kolonin MG, Daquinag AC, Brandi L, Warraich I, San Francisco SK, Sun X, Fan Z, Wang S
Journal of controlled release : official journal of the Controlled Release Society
Browning white adipose tissue using adipose stromal cell-targeted resveratrol-loaded nanoparticles for combating obesity. J Control Release. 2021 May 10; 333:339-351.
Browning white adipose tissue using adipose stromal cell-targeted resveratrol-loaded nanoparticles for combating obesity.
Cui J, Shu C, Xu J, Chen D, Li J, Ding K, Chen M, Li A, He J, Shu Y, Yang L, Zhang R, Zhou J
JP1 suppresses proliferation and metastasis of melanoma through MEK1/2 mediated NEDD4L-SP1-Integrin avß3 signaling. Theranostics. 2020; 10(18):8036-8050.
JP1 suppresses proliferation and metastasis of melanoma through MEK1/2 mediated NEDD4L-SP1-Integrin avß3 signaling.
Punganuru SR, Madala HR, Arutla V, Zhang R, Srivenugopal KS
Characterization of a highly specific NQO1-activated near-infrared fluorescent probe and its application for in vivo tumor imaging. Sci Rep. 2019 Jun 12; 9(1):8577.
Characterization of a highly specific NQO1-activated near-infrared fluorescent probe and its application for in vivo tumor imaging.
Preface. Curr Cancer Drug Targets. 2019; 19(1):2.
Preface. Curr Cancer Drug Targets. 2018; 18(1):2.
Madala HR, Punganuru SR, Ali-Osman F, Zhang R, Srivenugopal KS
Brain- and brain tumor-penetrating disulfiram nanoparticles: Sequence of cytotoxic events and efficacy in human glioma cell lines and intracranial xenografts. Oncotarget. 2018 Jan 09; 9(3):3459-3482.
Brain- and brain tumor-penetrating disulfiram nanoparticles: Sequence of cytotoxic events and efficacy in human glioma cell lines and intracranial xenografts.
Li X, Ba Q, Liu Y, Yue Q, Chen P, Li J, Zhang H, Ying H, Ding Q, Song H, Liu H, Zhang R, Wang H
Dihydroartemisinin selectively inhibits PDGFRa-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRa protein. Cell Discov. 2017; 3:17042.
Dihydroartemisinin selectively inhibits PDGFRa-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRa protein.
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy
MDM2 ONCOGENE AS A TARGET FOR MODULATING CANCER THERAPY
MDM2 AS A NEGATIVE REGULATOR OF P21 WAF1/CIP1
Dietary Chemopreventive Components/Oncogene Interaction and Cancer
Novel NFAT1-MDM2 inhibitor for Breast Cancer Therapy